In the BioHarmony Drug Report Database
Serentil (mesoridazine) is a small molecule pharmaceutical. Mesoridazine was first approved as Serentil on 1982-01-01. It is used to treat alcoholism, psychotic disorders, and schizophrenia in the USA. It is known to target 5-hydroxytryptamine receptor 2C, D(3) dopamine receptor, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 1A, D(1A) dopamine receptor, and D(2) dopamine receptor.
Image (chem structure or protein)